Efficacy and safety of abrocitinib in elderly Chinese patients with moderate-to-severe AD: a single-center, retrospective study
Description
Supplemental data of abrocitinib improves both physician- and patient-reported outcomes in elderly Chinese patients with moderate-to-severe AD. Figure S1. Abrocitinib improves both physician- and patient-reported outcomes in elderly Chinese patients with moderate-to-severe AD. (a) Distribution of Investigator’s Global Assessment (IGA) scores at baseline (BL) and last visit (LV), and 85.7% of patients achieved IGA score of 0 or 1; (b) The median EASI score improved from 20.6 [15.3, 31.7] at BL to 3.6 [2.0, 5.7] at LV; (c) Peak Pruritus Numerical Rating Scale (PP-NRS) scores decreased from 8 [7, 9] at BL to 2 [1, 3] at LV; (d) Dermatology Life Quality Index (DLQI) scores improved from 16.5 [13.3, 19.8] at BL to 4 [2, 5] at LV. IGA response proportions were compared using the Chi-square test for trend. Changes in EASI, PP-NRS, and DLQI scores from BL to lV were analyzed using the Wilcoxon signed-rank test. ****P < 0.0001. sTable1. Clinical outcomes in moderate-to-severe elderly Chinese AD patients treated with abrocitinib.